Status:
TERMINATED
ADX10059 Migraine Prevention Study
Lead Sponsor:
Addex Pharma S.A.
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Evaluation of ADX10059 to prevent migraine attacks
Eligibility Criteria
Inclusion
- Male and female patients aged 18 to 65 years
- History of migraine
- Aged ≤ 50 years at onset of migraine history
Exclusion
- Cluster headache or chronic migraine headaches
- Currently uses, or within 3 months of Screening, has used: sodium valproate or topiramate and any other drugs used specifically for migraine prophylaxis, for example beta-blockers, calcium channel blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors
- Unable to distinguish migraine headache from tension and other types of headache
- Current history of psychiatric disorder requiring regular medication
- Known history of alcohol abuse
- Known clinically significant allergy or known hypersensitivity to drugs
- History of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study
- Pregnant or breast-feeding
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00820105
Start Date
December 1 2008
Last Update
December 24 2009
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna, Austria
2
Liège
Liège, Belgium
3
Sint-Truiden
Sint-Truiden, Belgium
4
Wilrijk
Wilrijk, Belgium